[go: up one dir, main page]

EA200971100A1 - Производные фталазинона в качестве ингибиторов поли(адф-рибоза)полимеразы (parp-1) - Google Patents

Производные фталазинона в качестве ингибиторов поли(адф-рибоза)полимеразы (parp-1)

Info

Publication number
EA200971100A1
EA200971100A1 EA200971100A EA200971100A EA200971100A1 EA 200971100 A1 EA200971100 A1 EA 200971100A1 EA 200971100 A EA200971100 A EA 200971100A EA 200971100 A EA200971100 A EA 200971100A EA 200971100 A1 EA200971100 A1 EA 200971100A1
Authority
EA
Eurasian Patent Office
Prior art keywords
possibly substituted
group
crr
possibly
substituted
Prior art date
Application number
EA200971100A
Other languages
English (en)
Inventor
Мухаммед Хашим Джавайд
Кейт Алан Менеар
Найэл Моррисон Бар Мартин
Грэм Камерон Мюррей Смит
Дэвид Алан Радж
Крейг Энтони Робертс
Original Assignee
Астразенека Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Астразенека Аб filed Critical Астразенека Аб
Publication of EA200971100A1 publication Critical patent/EA200971100A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)

Abstract

В настоящем изобретении предложено соединение формулы (I)где R представляет собой один или более возможных заместителей в конденсированном циклогексеновом кольце; Х может представлять собой NRили CRRесли Х=NRто n равно 1 или 2, и если Х=CRR, то n равно 1; если Х=NRто Rвыбран из группы, состоящей из H, возможно замещённого Cалкила, возможно замещённого Cарила, возможно замещённого Сгетероциклила, возможно замещённой амидогруппы, возможно замещённой тиоамидогруппы, возможно замещённого сложного эфира, возможно замещённого ацила и возможно замещённой сульфонильной группы; если Х=CRRто Rвыбран из группы, состоящей из Н, возможно замещённого Cалкила, возможно замещённого Cарила, возможно замещённого Сгетероциклила, возможно замещённой амидогруппы, возможно замещённой тиоамидогруппы, возможно замещённой сульфонаминогруппы, возможно замещённой простоэфирной группы, возможно замещённой сложноэфирной группы, возможно замещённой ацильной группы, возможно замещённой ациламидогруппы и возможно замещённой сульфонильной группы, а Rвыбран из Н, гидроксила и возможно замещённой аминогруппы, или Rи Rсовместно могут образовывать возможно замещённую спиро-Сциклоалкильную или гетероциклильную группу; каждый из Rи Rпредставляет собой водород, или если Х представляет собой CRR, R, R, Rи R, совместно с атомами углерода, к которым они присоединены, могут образовывать возможно замещённое конденсированное ароматическое кольцо; и Rвыбран из Н и галогена. Предложенные соединения выступают в качестве ингибиторов поли(АДФ-рибоза)синтазы, PARP-1.
EA200971100A 2007-07-05 2008-07-04 Производные фталазинона в качестве ингибиторов поли(адф-рибоза)полимеразы (parp-1) EA200971100A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94800807P 2007-07-05 2007-07-05
US3263508P 2008-02-29 2008-02-29
PCT/GB2008/002318 WO2009004356A1 (en) 2007-07-05 2008-07-04 Phthalazinone derivatives as inhibitors of parp-1

Publications (1)

Publication Number Publication Date
EA200971100A1 true EA200971100A1 (ru) 2010-06-30

Family

ID=39744797

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200971100A EA200971100A1 (ru) 2007-07-05 2008-07-04 Производные фталазинона в качестве ингибиторов поли(адф-рибоза)полимеразы (parp-1)

Country Status (20)

Country Link
US (1) US20090023727A1 (ru)
EP (1) EP2176237A1 (ru)
JP (1) JP2010532339A (ru)
KR (1) KR20100044816A (ru)
CN (1) CN101848898A (ru)
AR (1) AR067460A1 (ru)
AU (1) AU2008272667A1 (ru)
BR (1) BRPI0812825A2 (ru)
CA (1) CA2691459A1 (ru)
CL (1) CL2008001983A1 (ru)
CO (1) CO6251253A2 (ru)
CR (1) CR11181A (ru)
DO (1) DOP2009000288A (ru)
EA (1) EA200971100A1 (ru)
EC (1) ECSP099813A (ru)
IL (1) IL202834A0 (ru)
MX (1) MX2009013800A (ru)
SV (1) SV2009003437A (ru)
TW (1) TW200908980A (ru)
WO (1) WO2009004356A1 (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2564527C2 (ru) * 2010-08-09 2015-10-10 Цзянсу Хансох Фармасьютикал Ко., Лтд. Производное фталазинонкетона, способ его получения и его фармацевтическое применение

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0610680D0 (en) 2006-05-31 2006-07-12 Istituto Di Ricerche D Biolog Therapeutic compounds
MX2010005070A (es) 2007-11-15 2010-05-24 Angeletti P Ist Richerche Bio Derivados de piridazinona como inhibidores de parp.
AR070221A1 (es) * 2008-01-23 2010-03-25 Astrazeneca Ab Derivados de ftalazinona inhibidores de polimerasas, composiciones farmaceuticas que los contienen y usos de los mismos para prevenir y/o tratar tumores cancerigenos,lesiones isquemicas y otras enfermedades asociadas.
US8889674B2 (en) 2009-03-05 2014-11-18 Shionogi & Co., Ltd. Piperidine and pyrrolidine derivatives having NPY Y5 receptor antagonism
UY32790A (es) * 2009-07-15 2011-02-28 Astrazeneca Ab Compuesto de ftalazinona
WO2011058367A2 (en) 2009-11-13 2011-05-19 Astrazeneca Ab Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor
CN102372706A (zh) * 2010-08-09 2012-03-14 江苏恒瑞医药股份有限公司 酞嗪酮类衍生物、其制备方法及其在医药上的应用
CN102372698A (zh) * 2010-08-10 2012-03-14 江苏恒瑞医药股份有限公司 酞嗪酮类衍生物、其制备方法及其在医药上的应用
WO2012071684A1 (en) 2010-12-02 2012-06-07 Shanghai De Novo Pharmatech Co Ltd. Heterocyclic derivates，preparation processes and medical uses thereof
EP2686305B1 (en) * 2011-03-14 2020-09-16 Impact Therapeutics, Inc. Quinazolinediones and their use
EP2714703B1 (en) 2011-05-31 2021-03-10 Newgen Therapeutics, Inc. Tricyclic inhibitors of poly(adp-ribose)polymerase
US9102631B2 (en) * 2011-11-01 2015-08-11 Impact Therapeutics, Inc. 1-(arylmethyl)-5,6,7,8-tetrahydroquinazoline-2,4-diones and analogs and the use thereof
CN103833756B (zh) * 2012-11-26 2016-12-21 中国科学院上海药物研究所 一类哒嗪酮类化合物及其制备方法和用途
WO2014102817A1 (en) 2012-12-31 2014-07-03 Cadila Healthcare Limited Substituted phthalazin-1 (2h)-one derivatives as selective inhibitors of poly (adp-ribose) polymerase-1
EP3587406B1 (en) 2013-03-13 2021-01-27 Forma Therapeutics, Inc. 2-hydroxy-1-{4-[(4-phenylphenyl)carbonyl]piperazin-1-yl}ethan-1-one derivatives and related compounds as fatty acid synthase (fasn) inhibitors for the treatment of cancer
PT3448859T (pt) 2017-03-20 2019-10-25 Forma Therapeutics Inc Composições de pirrolopirrole como ativadores de piruvato quinase (pkr).
CA3096127A1 (en) 2017-04-28 2018-11-01 Akribes Biomedical Gmbh A parp inhibitor in combination with a glucocorticoid and/or ascorbic acid and/or a protein growth factor for the treatment of impaired wound healing
CN108164468B (zh) * 2018-02-09 2021-02-02 上海卫岑医药科技有限公司 一种parp抑制剂、其药物组合物、制备方法及应用
US12053458B2 (en) 2018-09-19 2024-08-06 Novo Nordisk Health Care Ag Treating sickle cell disease with a pyruvate kinase R activating compound
ES2989438T3 (es) 2018-09-19 2024-11-26 Novo Nordisk Healthcare Ag Activación de la piruvato cinasa R
TWI767148B (zh) 2018-10-10 2022-06-11 美商弗瑪治療公司 抑制脂肪酸合成酶(fasn)
CN113382633A (zh) 2018-10-29 2021-09-10 福马治疗股份有限公司 (4-(2-氟-4-(1-甲基-1H-苯并[d]咪唑-5-基)苯甲酰基)哌嗪-1-基)(1-羟基环丙基)甲酮的固体形式
TWI837403B (zh) * 2019-07-19 2024-04-01 瑞典商阿斯特捷利康公司 化學化合物
CN114615977B (zh) 2019-09-19 2025-01-14 诺沃挪第克健康护理股份公司 丙酮酸激酶r(pkr)活化组合物
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R
JP2024539252A (ja) * 2021-10-28 2024-10-28 ギリアード サイエンシーズ， インコーポレイテッド ピリジジン－３（２ｈ）－オン誘導体
WO2025183523A1 (ko) * 2024-02-29 2025-09-04 아주대학교 산학협력단 Parp 억제제 감수성 증가 방법

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3813384A (en) * 1972-01-17 1974-05-28 Asta Werke Ag Chem Fab Basically substituted benzyl phthalazone derivatives,acid salts thereof and process for the production thereof
US4665181A (en) * 1984-05-17 1987-05-12 Pennwalt Corporation Anti-inflammatory phthalazinones
US5215738A (en) * 1985-05-03 1993-06-01 Sri International Benzamide and nicotinamide radiosensitizers
US5032617A (en) * 1985-05-03 1991-07-16 Sri International Substituted benzamide radiosensitizers
US5041653A (en) * 1985-05-03 1991-08-20 Sri International Substituted benzamide radiosensitizers
ATE60598T1 (de) * 1985-11-11 1991-02-15 Asta Pharma Ag 4-benzyl-1-(2h)-phthalazinon-derivate.
DE3640641A1 (de) * 1986-11-28 1988-07-14 Thomae Gmbh Dr K Neue heteroaromatische aminderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
CZ199593A3 (en) * 1992-10-02 1994-04-13 Asta Medica Ag Phthalazinone derivatives exhibiting anti-arrhythmic and analgesic activity and eliminating resistance to a plurality of medicaments (mdr)
US5587384A (en) * 1994-02-04 1996-12-24 The Johns Hopkins University Inhibitors of poly(ADP-ribose) synthetase and use thereof to treat NMDA neurotoxicity
US5648355A (en) * 1994-02-09 1997-07-15 Kos Pharmaceutical, Inc. Method of treatment of endogenous, painful gastrointestinal conditions of non-inflammatory, non-ulcerative origin
US5589483A (en) * 1994-12-21 1996-12-31 Geron Corporation Isoquinoline poly (ADP-ribose) polymerase inhibitors to treat skin diseases associated with cellular senescence
CN1136197C (zh) * 1996-05-30 2004-01-28 霍夫曼-拉罗奇有限公司 新的哒嗪酮衍生物
CO4950519A1 (es) * 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
US6514983B1 (en) * 1997-09-03 2003-02-04 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage
US6197785B1 (en) * 1997-09-03 2001-03-06 Guilford Pharmaceuticals Inc. Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity
US6426415B1 (en) * 1997-09-03 2002-07-30 Guilford Pharmaceuticals Inc. Alkoxy-substituted compounds, methods and compositions for inhibiting parp activity
US6635642B1 (en) * 1997-09-03 2003-10-21 Guilford Pharmaceuticals Inc. PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same
WO1999025340A1 (en) * 1997-11-14 1999-05-27 Eli Lilly And Company Treatment for alzheimer's disease
ITMI981671A1 (it) * 1998-07-21 2000-01-21 Zambon Spa Derivati ftalazinici inibitori della fosfodisterasi 4
EP1148053A4 (en) * 1999-01-26 2002-03-06 Ono Pharmaceutical Co 2H-PHTHALAZIN-1-ON DERIVATIVES AND DRUG COMPOSITIONS THAT CONTAIN THESE DERIVATIVES AS ACTIVE INGREDIENTS
DE19921567A1 (de) * 1999-05-11 2000-11-16 Basf Ag Verwendung von Phthalazine-Derivaten
US6476048B1 (en) * 1999-12-07 2002-11-05 Inotek Pharamaceuticals Corporation Substituted phenanthridinones and methods of use thereof
ATE372337T1 (de) * 2000-02-01 2007-09-15 Abbott Gmbh & Co Kg Heterozyklische verbindungen und deren anwendung als parp-inhibitoren
DE10022925A1 (de) * 2000-05-11 2001-11-15 Basf Ag Substituierte Indole als PARP-Inhibitoren
US7151102B2 (en) * 2000-10-30 2006-12-19 Kudos Pharmaceuticals Limited Phthalazinone derivatives
US20040176361A1 (en) * 2001-05-23 2004-09-09 Masakazu Fujio Fused heterocyclic compound and medicinal use thereof
AUPS019702A0 (en) * 2002-01-29 2002-02-21 Fujisawa Pharmaceutical Co., Ltd. Condensed heterocyclic compounds
PL372171A1 (en) * 2002-02-19 2005-07-11 Ono Pharmaceutical Co, Ltd. Fused pyridazine derivative compounds and drugs containing the compounds as the active ingredient
AU2003229953A1 (en) * 2002-04-30 2003-11-17 Kudos Pharmaceuticals Limited Phthalazinone derivatives
BRPI0408284B8 (pt) * 2003-03-12 2021-05-25 Kudos Pharm Ltd compostos derivados de ftalazinona, seu uso e composição farmacêutica compreendendo os mesmos
WO2005053662A1 (en) * 2003-12-01 2005-06-16 Kudos Pharmaceuticals Limited Dna damage repair inhibitors for treatment of cancer
GB0419072D0 (en) * 2004-08-26 2004-09-29 Kudos Pharm Ltd Phthalazinone derivatives
GB0521373D0 (en) * 2005-10-20 2005-11-30 Kudos Pharm Ltd Pthalazinone derivatives
DK2120579T3 (da) * 2006-12-28 2014-02-03 Abbvie Inc Inhibitorer af poly(ADP-ripose)polymerase
US20110098304A1 (en) * 2008-10-22 2011-04-28 Bijoy Panicker Small molecule inhibitors of PARP activity

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2564527C2 (ru) * 2010-08-09 2015-10-10 Цзянсу Хансох Фармасьютикал Ко., Лтд. Производное фталазинонкетона, способ его получения и его фармацевтическое применение

Also Published As

Publication number Publication date
TW200908980A (en) 2009-03-01
MX2009013800A (es) 2010-01-29
WO2009004356A1 (en) 2009-01-08
CR11181A (es) 2010-07-20
AR067460A1 (es) 2009-10-14
CL2008001983A1 (es) 2008-10-24
DOP2009000288A (es) 2010-03-31
SV2009003437A (es) 2010-05-17
EP2176237A1 (en) 2010-04-21
CO6251253A2 (es) 2011-02-21
CN101848898A (zh) 2010-09-29
AU2008272667A1 (en) 2009-01-08
IL202834A0 (en) 2010-06-30
BRPI0812825A2 (pt) 2014-12-09
ECSP099813A (es) 2010-01-29
CA2691459A1 (en) 2009-01-08
JP2010532339A (ja) 2010-10-07
US20090023727A1 (en) 2009-01-22
KR20100044816A (ko) 2010-04-30

Similar Documents

Publication Publication Date Title
EA200971100A1 (ru) Производные фталазинона в качестве ингибиторов поли(адф-рибоза)полимеразы (parp-1)
AR067613A1 (es) Inhibidores de adn-pk, uso y sintesis de los mismos
EA201101089A1 (ru) Производные оксадиазола в качестве агонистов рецептора s1p1
UA109525C2 (xx) Алкіламідна сполука і її застосування
PE20061417A1 (es) Metodo para sintetizar 3-cianoquinolinas sustituidas y sus intermediarios
NI201000120A (es) Derivados de ftalazinona
AR061369A1 (es) Derivados de pirimidina y composiciones farmaceuticas que los comprenden
EA200970461A1 (ru) ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ 3-ИЗОБУТИЛ-9,10-ДИМЕТОКСИ-1,3,4,6,7,11b-ГЕКСАГИДРО-2Н-ПИРИДО[2,1-a]ИЗОХИНОЛИН-2-ОЛА И СВЯЗАННЫЕ С НИМИ СПОСОБЫ
NO20054625L (no) Ftalazinonderivater
CY1112914T1 (el) Υποκατεστημενα παραγωγα ινδολυλ αλκυλ αμινης ως νεοι αναστολεις των αποακετυλασων ιστονης
PH12013501196B1 (en) Indeno- fused ring compounds having photochromic properties
MX339476B (es) Compuestos que incluyen un nucleo farmaceutico antiinflamatorio y sus metodos de uso.
ES2422204T3 (es) Novedosos derivados de imidazolidin-2-ona como moduladores selectivos de receptor de andrógenos (SARMS)
EA200970266A1 (ru) Азабициклические соединения в качестве ингибиторов повторного поглощения моноаминов
EA200970793A1 (ru) Модуляторы рецепторов, активируемых пролифераторами пероксисом
PE20100051A1 (es) Nuevo procedimiento de sintesis de 7,8-dimetoxi-1,3-dihidro-2h-3-benzazepin-2-oa y aplicacion en la sintesis de ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable
EA200401455A1 (ru) Производные бензоксазина в качестве модуляторов 5-htи их применение
CO6420345A2 (es) Tetrahidrobenzazepinas ariloxi- y heteroariloxi-siustituidas y su uso de la misma para bloquear reabsorcion de norepinefrina dopamina y serotonina
EA200971063A1 (ru) Ариламидпиримидоновые соединения
EA200971062A1 (ru) Производные ариламидпиримидона
EA201071296A1 (ru) Агонист глюкокортикоидного рецептора, включающий 2,2,4-триметил-6-фенил-1,2-дигидрохинолиновые производные, содержащие замещенную оксигруппу
EA200301317A1 (ru) Производные аминохинолина и его применение в качестве лигандов аденозина a3
ECSP088360A (es) Métodos para preparar derivados de ácido glutámico
AR059031A1 (es) Combinacion de derivados de triazina e inhibidores de la hmg- coa reductasa
CO6341516A2 (es) Composiciones pesticidas